AstraZeneca therapy improves survival in late-stage breast cancer trial

Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in patients with an advanced form of breast cancer without the disease getting worse in a late-stage clinical trial.